Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Docetaxel, trastuzumab|DRUG: Pyrotinib
Sponsor: Jiangsu HengRui Medicine Co., Ltd.